A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension (Phase IIIb).
Phase of Trial: Phase III
Latest Information Update: 10 May 2017
At a glance
- Drugs Fimasartan (Primary) ; Candesartan cilexetil
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Boryung Pharmaceutical
- 06 May 2016 Primary endpoint (Sitting Diastolic Blood Pressure) has not been met, according to results published in the Clinical Therapeutics.
- 06 May 2016 Results assessing antihypertensive efficacy of fimasartan published in the Clinical Therapeutics.
- 23 Aug 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.